Ilovetech, Licensing has some complexities. To get any substantial upfront cash, it requires total exclusivity. Then you are on their schedule (for the acquirer the cash is a sunk cost), so how quickly, and/if/or, they go to market, if it cannabalizes their drug, comes into question, and questions the royalty income forecast. There are some R&D companies that do it, and I do not want to criticize their model. I will just say I believe for realizing potential global growth, to be a BP, for maximizing the new and undiscovered opportunities in a novel drug/vaccine, I think it is best to be a product company.
Market Data 
Markets 
AI
